InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies
Biotech Begins to Demonstrate Strategy to Expand NHL
InNexus Biotechnology Inc. announced the results of an extensive mouse tumor study demonstrating superiority of InNexus' DXL625 (CD20) versus Rituxan(R) in the xenograft model.
InNexus plans to submit the data for publication along with additional data from animal studies recently completed and presented at the American Association for Cancer Research (AACR) 2008 Annual Conference. The company has also launched a large scale study of DXL625 with primates, designed to evaluate toxicity and pharmokinetics, enabling the company to move the product to the FDA toward human testing.
"A study performed by an independent group investigating the survival of mice intravenously injected with B-lymphoma cells and treated subsequently with DXL625 showed a significant improvement in outcome compared to animals treated with equivalent doses of Rituxan(R), a commercially available anti-CD20 antibody," said Dr.Thomas Kindt, InNexus' Chief Scientific Officer. "Animals treated with either drug had a superior outcome when compared to those receiving inactive control (vehicle), however DXL625 had a substantial advantage over the competing antibody. We are confident that these results will translate to therapeutic advantage when DXL625 is used in human subjects."
Other news from the department research and development
